An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Dalrada Health Advisory Board Expands to Support Business Growth
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management
Rhea-AI Summary
Dalrada Corporation (OTCQB: DFCO) announced the addition of three experienced members to its Advisory Board: Reynold Bryan Jr., Capt. Patrick Blair, Ph.D., and John Short. These industry veterans bring expertise in medical research, healthcare management, and business development. The new board members will support Dalrada Health's initiatives to enhance its value-based healthcare model, aiming to improve patient outcomes nationally. CEO Brian Bonar emphasized that their leadership will help expand Dalrada's life sciences and consumer products sectors for affordable healthcare solutions.
Positive
Appointment of experienced board members strengthens leadership and expertise.
Potential for innovative healthcare solutions through expanded knowledge base.
Alignment with national healthcare initiatives may enhance market competitiveness.
Negative
Concerns over continuity and experience gaps in the management team.
Addition of three industry veterans will advance national healthcare initiatives.
SAN DIEGO--(BUSINESS WIRE)--
Dalrada Corporation (OTCQB: DFCO, "Dalrada") today announced the appointments of Reynold Bryan Jr., U.S. Navy Capt. Patrick Blair, Ph.D., and John Short to Dalrada Health’s Advisory Board. These industry veterans bring vast experience across the healthcare industry, including medical research, workforce management and business development, and will support Dalrada Health as it expands into new areas of healthcare.
“We’re excited to welcome Reynold, Patrick, and John to our Advisory Board to diversify our knowledge base and help support Dalrada Health’s efforts to bring patients an end-to-end healthcare experience within a value-based care model,” said Brian Bonar, Chairman and CEO at Dalrada. “With their expert guidance, we will continue to grow our life sciences and consumer product sectors to create affordable, accessible healthcare solutions for all patients.”
Reynold Bryan Jr. is the general manager and managing director of Microsoft Corporation and managing principal for Healthcare Margins, LLC. He previously served in executive positions for Oracle Health Care Services, IBM Global Services, Extreme Networks and Accenture. Bryan is professionally associated with the American College of Healthcare Executives, the Healthcare Financial Management Association, the Health Information Management Systems Society, and the American Association of Health Plans. His proven leadership and expertise in advanced technology will enable Dalrada Health to expand its market share and drive product development.
U.S. Navy Capt. Patrick Blair, Ph.D., is an assistant professor at the College of Public Health and Tropical Medicine at Wake Forest University, an instructor for the Naval Ethics and Leadership Command, and serves as a consultant for the World Health Organization. He has extensive experience in virology, infectious diseases, immunology, vaccines, diagnostic testing, and product development. Capt. Blair has received numerous military awards, including the Delores M. Etter Award for the Navy’s Top Scientist in 2011, and has published 145 scientific manuscripts and book chapters throughout his career. Military awards recognizing Capt. Blair's achievements include the Legion of Merit Medal, Meritorious Service Medal (five times), Navy and Marine Corps Commendation Medal (three times), Navy Achievement Medal (two times), Air Force Achievement Medal, and Meritorious Unit Citation (two times).
John Short is a retired senior software executive with 30 years of leadership experience in healthcare workforce management. He previously served as the director of professional services for healthcare at UKG, Inc., (formerly Kronos, Inc.). Short’s healthcare management skills will help streamline operations to reduce patient costs and improve their health outcomes. Ultimately, his decades of experience will broaden Dalrada’s capabilities to expand its healthcare model.
The Advisory Board also recently appointed Elizabeth Winzeler, Ph.D., a professor in the Department of Pediatrics at the University of California, San Diego, School of Medicine.
Dalrada Health’s national healthcare model leverages advanced technology to increase positive patient outcomes in the U.S. Each newly-appointed board member will guide Dalrada Health as it accelerates this model to help address the population’s highest health priorities. Collectively, the Advisory Board will counsel senior leaders to advance Dalrada Health’s vision of providing equitable healthcare services and products to patients on a national level.
Dalrada Corporation leverages innovation to drive positive change that impacts people and the planet. Established in 1982, Dalrada is composed of four business divisions – Dalrada Health, Dalrada Energy Services, Dalrada Technologies and Dalrada Precision – each uniquely designed to address global issues with creative solutions. With its subsidiaries firmly positioned in the world’s top growing industries, Dalrada is accelerating possibilities for current and future generations. For more information, please visit www.dalrada.com, and follow us on Twitter, Facebook, and LinkedIn.
Disclaimer:
Statements in this press release are not historical facts, the statements are forward-looking, including statements regarding future revenues and sales projections, plans for future financing, the ability to meet operational milestones, marketing arrangements and plans, and shipments to and regulatory approvals in international markets. Such statements reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors and will be dependent upon a variety of factors including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our products and services in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations regarding these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the US Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K.
What recent appointments were made to Dalrada Corporation's Advisory Board?
Dalrada Corporation appointed Reynold Bryan Jr., Capt. Patrick Blair, Ph.D., and John Short to its Advisory Board to enhance its healthcare initiatives.
What expertise do the new board members bring to Dalrada Corporation?
The new members bring extensive backgrounds in healthcare management, medical research, and business development, which will support Dalrada Health's goals.
How will the new board members impact Dalrada Corporation's healthcare initiatives?
Their guidance is expected to bolster Dalrada Health's efforts in creating affordable, accessible healthcare solutions and improving patient outcomes.
What is the significance of these appointments for DFCO investors?
The appointments may enhance Dalrada's strategic direction and operational effectiveness, potentially leading to improved market performance for DFCO.
